JPWO2019150305A5 - - Google Patents

Claims (8)

28. The pharmaceutical composition of claim 27 for treating abnormal cell proliferation in humans. The pharmaceutical composition according to claim 29, wherein the abnormal cell proliferation is cancer. Cancers include lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, colon cancer, breast cancer, uterine cancer, Oviductal cancer, endometrial cancer, cervical cancer, vaginal cancer, genital cancer, Hodgkin's disease, esophageal cancer, small intestinal cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urinary tract cancer, penis cancer , Prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or urinary tract cancer, renal cell cancer, renal meng cancer, central nervous system (CNS) tumor, central nervous system primary lymphoma, spinal axis tumor, 30. The pharmaceutical composition according to claim 30, which is a brain stem glioma or a pituitary adenoma. 30. The pharmaceutical composition of claim 30, wherein the cancer is lung cancer, colon cancer, pancreatic cancer, and ovarian cancer. The use according to claim 30 or claim 34, wherein the cancer is associated with a KRAS mutant. The pharmaceutical composition or use according to claim 37, wherein the mutant is a G12C mutant. A drug for use in a method for treating cancer in a patient in need of treatment for the cancer .
(a) Confirm that the cancer is associated with the KRAS mutant; and
(b) Administering to a patient a therapeutically effective amount of the compound according to any one of claims 1-26 or a pharmaceutically acceptable salt thereof;
The above-mentioned medicine comprising the compound according to any one of claims 1 to 26 or a pharmaceutically acceptable salt thereof . The medicine according to claim 39, wherein the mutant is a G12C mutant.